Loading...
In a substantial policy revision, the U.S. Centers for Disease Control and Prevention (CDC) is now recommending pneumococcal conjugate vaccine for all adults who are 50 or older, not only for those who are ≥65 or at particularly high risk for infection. This change was prompted by models suggesting that lowering the vaccination age would increase uptake among both at-risk people and members of underserved populations. The change also was informed by the recent release of a 21-valent conjugate vaccine directed against a novel panel of pneumococcal serotypes (Capvaxive), with unique potential for preventing adult infections. Although the precise duration of protection from this and other conjugate vaccines is unknown, models suggest that peop…